/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Itamar - Biotechnologist & PhD Candidate in Cardio-Oncology
Graduate of Rutgers University and holder of a Master's in Molecular Medicine and Innovative Treatments (MMIT) from the University of Groningen. As a PhD candidate at the University Medical Center Groningen (UMCG), I am at the forefront of cardio-oncology research. My focus lies in exploring the molecular mechanisms of cardiotoxicity through the development of an AIC 3D engineered cardiac tissue model using iPSC technology.
Balancing my academic pursuits, I am deeply engaged in sports, particularly soccer, reflecting my dedication to teamwork and resilience. Eager to connect with fellow professionals and contribute to advancements in science and health.
CDK4/6 inhibitor ribociclib induces cardiotoxicity in dynamic engineered heart tissues, mitigated by E2F1 overexpression
Event: Frontiers in CardioVascular Biomedicine 2024
Topic: Stem Cells, Cell Cycle, Cell Senescence, Cell Death
Session: The immune system in the pathogenesis and treatment of cancer therapy-induced cardiovascular toxicity
